Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis (NCT05739435)

🧪 Interventions in This Study

• envudeucitinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (38 Sites)

Showing the first 25 of 38 sites.

• Investigator Site # 1029 — Birmingham, Alabama
• Investigator Site #1001 — Phoenix, Arizona
• Investigator Site # 1023 — Rogers, Arkansas
• Investigator Site #1021 — Encinitas, California
• Investigator Site #1018 — Los Angeles, California
• Investigator Site #1007 — Santa Monica, California
• Investigator Site #1002 — Sherman Oaks, California
• Investigator site # 1030 — Fort Lauderdale, Florida
• Investigator Site #1025 — Hialeah, Florida
• Investigator site # 1028 — Miami, Florida
• Investigator Site # 1013 — Tampa, Florida
• Investigator Site #1035 — Macon, Georgia
• Investigator Site #1043 — Sandy Springs, Georgia
• Investigator Site #1005 — Rolling Meadows, Illinois
• Investigator Site # 1011 — Columbus, Indiana
• Investigator Site #1027 — South Bend, Indiana
• Investigator SIte#1036 — Overland Park, Kansas
• Investigator Site #1017 — Owensboro, Kentucky
• Investigator Site #1026 — Rockville, Maryland
• Investigator Site #1010 — Clarkston, Michigan
• Investigator Site #1031 — New Brighton, Minnesota
• Investigator Site #1033 — Norman, Oklahoma
• Investigator Site #1019 — Portland, Oregon
• Investigator Site #1022 — Philadelphia, Pennsylvania
• Investigator Site # 1012 — Rapid City, South Dakota

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Plaque Psoriasis

• A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis — Phoenix, Arizona
• Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis — Phoenix, Arizona
• A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis — Birmingham, Alabama
• Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects — Rogers, Arkansas
• A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) — Phoenix, Arizona

Explore by condition: All Plaque Psoriasis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.